3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
2
Suspended
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
35
Breast Neoplasms
30
Prostatic Neoplasms
21
Colorectal Neoplasms
21
Leukemia, Myeloid, Acute
19
Pancreatic Neoplasms
17
Melanoma
17
Glioblastoma
16
Carcinoma, Non-Small-Cell Lung
16
Neoplasm Metastasis
15
Lung Neoplasms
13
Brain Neoplasms
13
Glioma
12
Carcinoma, Hepatocellular
12
Stomach Neoplasms
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Myelodysplastic Syndromes
11
Ovarian Neoplasms
9
Multiple Myeloma
9
Head and Neck Neoplasms
9
Triple Negative Breast Neoplasms
8
Lymphoma
8
Carcinoma, Renal Cell
8
Rectal Neoplasms
6
Leukemia
6
Hematologic Neoplasms
6
Esophageal Neoplasms
6
Uterine Cervical Neoplasms
5
Sarcoma
5
Recurrence
5
Interventions
talazoparib
1
CX 5461
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Interventional
×
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled